_id
6912ffe8ccc777a4e85d7899
Ticker
IDYA
Name
Ideaya Biosciences Inc
Exchange
NASDAQ
Address
5000 Shoreline Court, South San Francisco, CA, United States, 94080
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.ideayabio.com
Description
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Last Close
33.56
Volume
494528
Current Price
34.02
Change
1.3706793802145436
Last Updated
2025-12-01T09:12:15.399Z
Image
data:image/webp;base64,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
Ipo Date
2019-05-23T00:00:00.000Z
Market Cap
3122677248
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.8814
Sentiment Sources
5
Rating
4.6923
Target Price
49.4706
Strong Buy
10
Buy
2
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
207834000
Cost Of Revenue
1030000
Gross Profit
206804000
Operating Expenses
98352000
Operating Income
108452000
Interest Expense
-
Pretax Income
119244000
Net Income
119244000
Eps
1.3294997513571
Dividends Per Share
-
Shares Outstanding
87666408
Income Tax Expense
-
EBITDA
120274000
Operating Margin
52.18202988923852
Total Other Income Expense Net
10792000
Cash
298927000
Short Term Investments
487967000
Receivables
-
Inventories
-
Total Current Assets
802655000
Property Plant Equipment
31716000
Total Assets
1185136000
Payables
18433000
Short Term Debt
328000
Long Term Debt
-
Total Liabilities
93102000
Equity
1092034000
Depreciation
1030000
Change In Working Capital
11705000
Cash From Operations
142214000
Capital Expenditures
42000
Cash From Investing
41767000
Cash From Financing
301000
Net Change In Cash
184282000
PE
-
PB
2.7941288179305777
ROE
10.91944023720873
ROA
10.061630057647394
FCF
142172000
Fcf Percent
0.684065167393208
Piotroski FScore
4
Health Score
88
Deep Value Investing Score
7.5
Defensive Investing Score
7
Dividend Investing Score
3
Economic Moat Investing Score
9
Garp Investing Score
4
Growth Investing Score
2
Momentum Investing Score
2.5
Net Net Investing Score
4
Quality Investing Score
9
Value Investing Score
8.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
207834000
Quarters > 0 > income Statement > cost Of Revenue
1030000
Quarters > 0 > income Statement > gross Profit
206804000
Quarters > 0 > income Statement > operating Expenses
98352000
Quarters > 0 > income Statement > operating Income
108452000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
119244000
Quarters > 0 > income Statement > net Income
119244000
Quarters > 0 > income Statement > eps
1.3294997513571
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
89690878
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
120274000
Quarters > 0 > income Statement > operating Margin
52.18202988923852
Quarters > 0 > income Statement > total Other Income Expense Net
10792000
Quarters > 0 > balance Sheet > cash
298927000
Quarters > 0 > balance Sheet > short Term Investments
487967000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
802655000
Quarters > 0 > balance Sheet > property Plant Equipment
31716000
Quarters > 0 > balance Sheet > total Assets
1185136000
Quarters > 0 > balance Sheet > payables
18433000
Quarters > 0 > balance Sheet > short Term Debt
328000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
93102000
Quarters > 0 > balance Sheet > equity
1092034000
Quarters > 0 > cash Flow > net Income
119244000
Quarters > 0 > cash Flow > depreciation
1030000
Quarters > 0 > cash Flow > change In Working Capital
11705000
Quarters > 0 > cash Flow > cash From Operations
142214000
Quarters > 0 > cash Flow > capital Expenditures
42000
Quarters > 0 > cash Flow > cash From Investing
41767000
Quarters > 0 > cash Flow > cash From Financing
301000
Quarters > 0 > cash Flow > net Change In Cash
184282000
Quarters > 0 > ratios > PE
1.3294997513571
Quarters > 0 > ratios > PB
2.7941288179305777
Quarters > 0 > ratios > ROE
10.91944023720873
Quarters > 0 > ratios > ROA
10.061630057647394
Quarters > 0 > ratios > FCF
142172000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.684065167393208
Quarters > 0 > health Score
88
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
1233000
Quarters > 1 > income Statement > gross Profit
-1233000
Quarters > 1 > income Statement > operating Expenses
87573000
Quarters > 1 > income Statement > operating Income
-88806000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-77491000
Quarters > 1 > income Statement > net Income
-77491000
Quarters > 1 > income Statement > eps
-0.8758816348675287
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
88472000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-76258000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
11315000
Quarters > 1 > balance Sheet > cash
114645000
Quarters > 1 > balance Sheet > short Term Investments
555093000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
685602000
Quarters > 1 > balance Sheet > property Plant Equipment
32732000
Quarters > 1 > balance Sheet > total Assets
1041270000
Quarters > 1 > balance Sheet > payables
17270000
Quarters > 1 > balance Sheet > short Term Debt
318000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
81617000
Quarters > 1 > balance Sheet > equity
959653000
Quarters > 1 > cash Flow > net Income
-77491000
Quarters > 1 > cash Flow > depreciation
1233000
Quarters > 1 > cash Flow > change In Working Capital
4608000
Quarters > 1 > cash Flow > cash From Operations
-62474000
Quarters > 1 > cash Flow > capital Expenditures
663000
Quarters > 1 > cash Flow > cash From Investing
45918000
Quarters > 1 > cash Flow > cash From Financing
1205000
Quarters > 1 > cash Flow > net Change In Cash
-15351000
Quarters > 1 > ratios > PE
-0.8758816348675287
Quarters > 1 > ratios > PB
3.1363601635174385
Quarters > 1 > ratios > ROE
-8.074897905805537
Quarters > 1 > ratios > ROA
-7.441969902138734
Quarters > 1 > ratios > FCF
-63137000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
38
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
1133000
Quarters > 2 > income Statement > gross Profit
-1133000
Quarters > 2 > income Statement > operating Expenses
83256000
Quarters > 2 > income Statement > operating Income
-84389000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-72178000
Quarters > 2 > income Statement > net Income
-72178000
Quarters > 2 > income Statement > eps
-0.8168998143872516
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
88356000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-71045000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
12211000
Quarters > 2 > balance Sheet > cash
129996000
Quarters > 2 > balance Sheet > short Term Investments
562512000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
707872000
Quarters > 2 > balance Sheet > property Plant Equipment
33299000
Quarters > 2 > balance Sheet > total Assets
1100641000
Quarters > 2 > balance Sheet > payables
17631000
Quarters > 2 > balance Sheet > short Term Debt
308000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
76506000
Quarters > 2 > balance Sheet > equity
1024135000
Quarters > 2 > cash Flow > net Income
-72178000
Quarters > 2 > cash Flow > depreciation
1133000
Quarters > 2 > cash Flow > change In Working Capital
4244000
Quarters > 2 > cash Flow > cash From Operations
-60342000
Quarters > 2 > cash Flow > capital Expenditures
1330000
Quarters > 2 > cash Flow > cash From Investing
79817000
Quarters > 2 > cash Flow > cash From Financing
26143000
Quarters > 2 > cash Flow > net Change In Cash
45618000
Quarters > 2 > ratios > PE
-0.8168998143872516
Quarters > 2 > ratios > PB
2.9350340726564372
Quarters > 2 > ratios > ROE
-7.047703671879195
Quarters > 2 > ratios > ROA
-6.55781494601782
Quarters > 2 > ratios > FCF
-61672000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
43
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
7000000
Quarters > 3 > income Statement > cost Of Revenue
643000
Quarters > 3 > income Statement > gross Profit
6357000
Quarters > 3 > income Statement > operating Expenses
150495000
Quarters > 3 > income Statement > operating Income
-144138000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-130312000
Quarters > 3 > income Statement > net Income
-130312000
Quarters > 3 > income Statement > eps
-1.4919952950259487
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
87340758
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-129669000
Quarters > 3 > income Statement > operating Margin
-2059.1142857142854
Quarters > 3 > income Statement > total Other Income Expense Net
13826000
Quarters > 3 > balance Sheet > cash
84378000
Quarters > 3 > balance Sheet > short Term Investments
591941000
Quarters > 3 > balance Sheet > receivables
3000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
689713000
Quarters > 3 > balance Sheet > property Plant Equipment
27741000
Quarters > 3 > balance Sheet > total Assets
1124091000
Quarters > 3 > balance Sheet > payables
15421000
Quarters > 3 > balance Sheet > short Term Debt
298000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
64944000
Quarters > 3 > balance Sheet > equity
1059147000
Quarters > 3 > cash Flow > net Income
-130312000
Quarters > 3 > cash Flow > depreciation
643000
Quarters > 3 > cash Flow > change In Working Capital
469000
Quarters > 3 > cash Flow > cash From Operations
-121655000
Quarters > 3 > cash Flow > capital Expenditures
1102000
Quarters > 3 > cash Flow > cash From Investing
-197109000
Quarters > 3 > cash Flow > cash From Financing
2753000
Quarters > 3 > cash Flow > net Change In Cash
-316011000
Quarters > 3 > ratios > PE
-1.4919952950259487
Quarters > 3 > ratios > PB
2.8054015043804124
Quarters > 3 > ratios > ROE
-12.303485729554065
Quarters > 3 > ratios > ROA
-11.592655754738718
Quarters > 3 > ratios > FCF
-122757000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-17.536714285714286
Quarters > 3 > health Score
35
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
7000000
Annuals > 0 > income Statement > cost Of Revenue
3834000
Annuals > 0 > income Statement > gross Profit
3166000
Annuals > 0 > income Statement > operating Expenses
330141000
Annuals > 0 > income Statement > operating Income
-326975000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-274477000
Annuals > 0 > income Statement > net Income
-274477000
Annuals > 0 > income Statement > eps
-3.3604736664379273
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
81678069
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-270643000
Annuals > 0 > income Statement > operating Margin
-4671.071428571429
Annuals > 0 > income Statement > total Other Income Expense Net
52498000
Annuals > 0 > balance Sheet > cash
84378000
Annuals > 0 > balance Sheet > short Term Investments
591941000
Annuals > 0 > balance Sheet > receivables
3000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
689713000
Annuals > 0 > balance Sheet > property Plant Equipment
27741000
Annuals > 0 > balance Sheet > total Assets
1124091000
Annuals > 0 > balance Sheet > payables
15421000
Annuals > 0 > balance Sheet > short Term Debt
298000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
64944000
Annuals > 0 > balance Sheet > equity
1059147000
Annuals > 0 > cash Flow > net Income
-274477000
Annuals > 0 > cash Flow > depreciation
3834000
Annuals > 0 > cash Flow > change In Working Capital
11546000
Annuals > 0 > cash Flow > cash From Operations
-247584000
Annuals > 0 > cash Flow > capital Expenditures
3857000
Annuals > 0 > cash Flow > cash From Investing
-502559000
Annuals > 0 > cash Flow > cash From Financing
677551000
Annuals > 0 > cash Flow > net Change In Cash
-72592000
Annuals > 0 > ratios > PE
-3.3604736664379273
Annuals > 0 > ratios > PB
2.7469018160651917
Annuals > 0 > ratios > ROE
-25.91491077253677
Annuals > 0 > ratios > ROA
-24.417685045071973
Annuals > 0 > ratios > FCF
-251441000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-35.92014285714286
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
23385000
Annuals > 1 > income Statement > cost Of Revenue
4008000
Annuals > 1 > income Statement > gross Profit
19377000
Annuals > 1 > income Statement > operating Expenses
153806000
Annuals > 1 > income Statement > operating Income
-134429000
Annuals > 1 > income Statement > interest Expense
21468000
Annuals > 1 > income Statement > pretax Income
-112961000
Annuals > 1 > income Statement > net Income
-112961000
Annuals > 1 > income Statement > eps
-1.9638584741646674
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
57519929
Annuals > 1 > income Statement > income Tax Expense
3840105
Annuals > 1 > income Statement > EBITDA
-108953000
Annuals > 1 > income Statement > operating Margin
-574.851400470387
Annuals > 1 > income Statement > total Other Income Expense Net
21468000
Annuals > 1 > balance Sheet > cash
157018000
Annuals > 1 > balance Sheet > short Term Investments
368096000
Annuals > 1 > balance Sheet > receivables
18000
Annuals > 1 > balance Sheet > inventories
532614000
Annuals > 1 > balance Sheet > total Current Assets
532632000
Annuals > 1 > balance Sheet > property Plant Equipment
8410000
Annuals > 1 > balance Sheet > total Assets
649316000
Annuals > 1 > balance Sheet > payables
6598000
Annuals > 1 > balance Sheet > short Term Debt
1747000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
28226000
Annuals > 1 > balance Sheet > equity
621090000
Annuals > 1 > cash Flow > net Income
-112961000
Annuals > 1 > cash Flow > depreciation
4008000
Annuals > 1 > cash Flow > change In Working Capital
-13207000
Annuals > 1 > cash Flow > cash From Operations
-115224000
Annuals > 1 > cash Flow > capital Expenditures
2368000
Annuals > 1 > cash Flow > cash From Investing
-158456000
Annuals > 1 > cash Flow > cash From Financing
362717000
Annuals > 1 > cash Flow > net Change In Cash
89037000
Annuals > 1 > ratios > PE
-1.9638584741646674
Annuals > 1 > ratios > PB
3.2988131687517104
Annuals > 1 > ratios > ROE
-18.18754125811074
Annuals > 1 > ratios > ROA
-17.396922299773916
Annuals > 1 > ratios > FCF
-117592000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-5.028522557194783
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
50931000
Annuals > 2 > income Statement > cost Of Revenue
2101000
Annuals > 2 > income Statement > gross Profit
50931000
Annuals > 2 > income Statement > operating Expenses
113433000
Annuals > 2 > income Statement > operating Income
-62502000
Annuals > 2 > income Statement > interest Expense
3847000
Annuals > 2 > income Statement > pretax Income
-58655000
Annuals > 2 > income Statement > net Income
-54808000
Annuals > 2 > income Statement > eps
-1.3224370134118006
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
41444696
Annuals > 2 > income Statement > income Tax Expense
-3847000
Annuals > 2 > income Statement > EBITDA
-60401000
Annuals > 2 > income Statement > operating Margin
-122.71897272780821
Annuals > 2 > income Statement > total Other Income Expense Net
3847000
Annuals > 2 > balance Sheet > cash
68632000
Annuals > 2 > balance Sheet > short Term Investments
296197000
Annuals > 2 > balance Sheet > receivables
211000
Annuals > 2 > balance Sheet > inventories
-8317000
Annuals > 2 > balance Sheet > total Current Assets
370454000
Annuals > 2 > balance Sheet > property Plant Equipment
8993000
Annuals > 2 > balance Sheet > total Assets
387969000
Annuals > 2 > balance Sheet > payables
4280000
Annuals > 2 > balance Sheet > short Term Debt
1871000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
38514000
Annuals > 2 > balance Sheet > equity
349455000
Annuals > 2 > cash Flow > net Income
-58655000
Annuals > 2 > cash Flow > depreciation
2101000
Annuals > 2 > cash Flow > change In Working Capital
-41555000
Annuals > 2 > cash Flow > cash From Operations
-87175000
Annuals > 2 > cash Flow > capital Expenditures
3443000
Annuals > 2 > cash Flow > cash From Investing
-33404000
Annuals > 2 > cash Flow > cash From Financing
97165000
Annuals > 2 > cash Flow > net Change In Cash
-23414000
Annuals > 2 > ratios > PE
-1.3224370134118006
Annuals > 2 > ratios > PB
4.224464012591034
Annuals > 2 > ratios > ROE
-15.683850567311957
Annuals > 2 > ratios > ROA
-14.126901891645982
Annuals > 2 > ratios > FCF
-90618000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-1.7792307239205984
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
27941000
Annuals > 3 > income Statement > cost Of Revenue
1725000
Annuals > 3 > income Statement > gross Profit
27941000
Annuals > 3 > income Statement > operating Expenses
78209000
Annuals > 3 > income Statement > operating Income
-50268000
Annuals > 3 > income Statement > interest Expense
506000
Annuals > 3 > income Statement > pretax Income
-49762000
Annuals > 3 > income Statement > net Income
-47531000
Annuals > 3 > income Statement > eps
-1.3483037189791358
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
35252443
Annuals > 3 > income Statement > income Tax Expense
-2231000
Annuals > 3 > income Statement > EBITDA
-48543000
Annuals > 3 > income Statement > operating Margin
-179.907662574711
Annuals > 3 > income Statement > total Other Income Expense Net
506000
Annuals > 3 > balance Sheet > cash
92046000
Annuals > 3 > balance Sheet > short Term Investments
154724000
Annuals > 3 > balance Sheet > receivables
1103000
Annuals > 3 > balance Sheet > inventories
-121293000
Annuals > 3 > balance Sheet > total Current Assets
250996000
Annuals > 3 > balance Sheet > property Plant Equipment
8661000
Annuals > 3 > balance Sheet > total Assets
381347000
Annuals > 3 > balance Sheet > payables
2100000
Annuals > 3 > balance Sheet > short Term Debt
1699000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
79833000
Annuals > 3 > balance Sheet > equity
301514000
Annuals > 3 > cash Flow > net Income
-49762000
Annuals > 3 > cash Flow > depreciation
1725000
Annuals > 3 > cash Flow > change In Working Capital
-17813000
Annuals > 3 > cash Flow > cash From Operations
-55779000
Annuals > 3 > cash Flow > capital Expenditures
2644000
Annuals > 3 > cash Flow > cash From Investing
-69666000
Annuals > 3 > cash Flow > cash From Financing
145454000
Annuals > 3 > cash Flow > net Change In Cash
20009000
Annuals > 3 > ratios > PE
-1.3483037189791358
Annuals > 3 > ratios > PB
4.164622603461199
Annuals > 3 > ratios > ROE
-15.764110455899228
Annuals > 3 > ratios > ROA
-12.463976378468953
Annuals > 3 > ratios > FCF
-58423000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-2.0909416269997494
Annuals > 3 > health Score
30
Valuation > metrics > PE
1.3294997513571
Valuation > metrics > PB
2.7941288179305777
Valuation > final Score
100
Valuation > verdict
43.4% Undervalued
Profitability > metrics > ROE
10.91944023720873
Profitability > metrics > ROA
14.856195999526573
Profitability > metrics > Net Margin
0.5737463552642975
Profitability > final Score
82
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
0.08525558728024951
Risk > metrics > Interest Coverage
105.29320388349515
Risk > final Score
100
Risk > verdict
Low
Liquidity > metrics > Current Ratio
42.78316720857097
Liquidity > metrics > Quick Ratio
42.78316720857097
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
48.63639836482562
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-228
Prev Risks > 1
-238
Prev Risks > 2
-837
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:39:21.500Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-31
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
-0.8633
Earnings History > 0 > eps Difference
0.8633
Earnings History > 0 > surprise Percent
100
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-04
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
1.33
Earnings History > 1 > eps Estimate
-0.55
Earnings History > 1 > eps Difference
1.88
Earnings History > 1 > surprise Percent
341.8182
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-05
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.88
Earnings History > 2 > eps Estimate
-0.79
Earnings History > 2 > eps Difference
-0.09
Earnings History > 2 > surprise Percent
-11.3924
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-06
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-0.82
Earnings History > 3 > eps Estimate
-0.69
Earnings History > 3 > eps Difference
-0.13
Earnings History > 3 > surprise Percent
-18.8406
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-02-18
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-1.49
Earnings History > 4 > eps Estimate
-0.6225
Earnings History > 4 > eps Difference
-0.8675
Earnings History > 4 > surprise Percent
-139.3574
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-05
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.6
Earnings History > 5 > eps Estimate
-0.63
Earnings History > 5 > eps Difference
0.03
Earnings History > 5 > surprise Percent
4.7619
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-06
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.68
Earnings History > 6 > eps Estimate
-0.54
Earnings History > 6 > eps Difference
-0.14
Earnings History > 6 > surprise Percent
-25.9259
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-07
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.53
Earnings History > 7 > eps Estimate
-0.51
Earnings History > 7 > eps Difference
-0.02
Earnings History > 7 > surprise Percent
-3.9216
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-02-20
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.52
Earnings History > 8 > eps Estimate
-0.47
Earnings History > 8 > eps Difference
-0.05
Earnings History > 8 > surprise Percent
-10.6383
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-07
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
BeforeMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-0.46
Earnings History > 9 > eps Estimate
-0.49
Earnings History > 9 > eps Difference
0.03
Earnings History > 9 > surprise Percent
6.1224
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-08-10
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.5
Earnings History > 10 > eps Estimate
-0.56
Earnings History > 10 > eps Difference
0.06
Earnings History > 10 > surprise Percent
10.7143
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-09
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
BeforeMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-0.49
Earnings History > 11 > eps Estimate
-0.55
Earnings History > 11 > eps Difference
0.06
Earnings History > 11 > surprise Percent
10.9091
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-03-07
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
BeforeMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-0.5
Earnings History > 12 > eps Estimate
-0.56
Earnings History > 12 > eps Difference
0.06
Earnings History > 12 > surprise Percent
10.7143
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-11-08
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
BeforeMarket
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
0.04
Earnings History > 13 > eps Estimate
-0.62
Earnings History > 13 > eps Difference
0.66
Earnings History > 13 > surprise Percent
106.4516
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-08-15
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
BeforeMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-0.57
Earnings History > 14 > eps Estimate
-0.52
Earnings History > 14 > eps Difference
-0.05
Earnings History > 14 > surprise Percent
-9.6154
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-05-10
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
BeforeMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
-0.36
Earnings History > 15 > eps Estimate
-0.41
Earnings History > 15 > eps Difference
0.05
Earnings History > 15 > surprise Percent
12.1951
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-03-15
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
BeforeMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-0.47
Earnings History > 16 > eps Estimate
-0.31
Earnings History > 16 > eps Difference
-0.16
Earnings History > 16 > surprise Percent
-51.6129
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-11-15
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
BeforeMarket
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-0.31
Earnings History > 17 > eps Estimate
-0.3
Earnings History > 17 > eps Difference
-0.01
Earnings History > 17 > surprise Percent
-3.3333
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-08-10
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
BeforeMarket
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-0.33
Earnings History > 18 > eps Estimate
-0.1
Earnings History > 18 > eps Difference
-0.23
Earnings History > 18 > surprise Percent
-230
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-05-10
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
BeforeMarket
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-0.28
Earnings History > 19 > eps Estimate
-0.27
Earnings History > 19 > eps Difference
-0.01
Earnings History > 19 > surprise Percent
-3.7037
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-03-23
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
BeforeMarket
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
-0.18
Earnings History > 20 > eps Estimate
-0.3
Earnings History > 20 > eps Difference
0.12
Earnings History > 20 > surprise Percent
40
Earnings History > 21 > period
2020-09-30
Earnings History > 21 > report Date
2020-11-12
Earnings History > 21 > date
2020-09-30
Earnings History > 21 > before After Market
BeforeMarket
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-0.17
Earnings History > 21 > eps Estimate
1.13
Earnings History > 21 > eps Difference
-1.3
Earnings History > 21 > surprise Percent
-115.0442
Earnings History > 22 > period
2020-06-30
Earnings History > 22 > report Date
2020-08-12
Earnings History > 22 > date
2020-06-30
Earnings History > 22 > before After Market
BeforeMarket
Earnings History > 22 > currency
USD
Earnings History > 22 > eps Actual
-0.59
Earnings History > 22 > eps Estimate
1.83
Earnings History > 22 > eps Difference
-2.42
Earnings History > 22 > surprise Percent
-132.2404
Earnings History > 23 > period
2020-03-31
Earnings History > 23 > report Date
2020-05-12
Earnings History > 23 > date
2020-03-31
Earnings History > 23 > before After Market
BeforeMarket
Earnings History > 23 > currency
USD
Earnings History > 23 > eps Actual
-0.59
Earnings History > 23 > eps Estimate
-0.57
Earnings History > 23 > eps Difference
-0.02
Earnings History > 23 > surprise Percent
-3.5088
Earnings History > 24 > period
2019-12-31
Earnings History > 24 > report Date
2020-03-24
Earnings History > 24 > date
2019-12-31
Earnings History > 24 > before After Market
BeforeMarket
Earnings History > 24 > currency
USD
Earnings History > 24 > eps Actual
-0.53
Earnings History > 24 > eps Estimate
-0.57
Earnings History > 24 > eps Difference
0.04
Earnings History > 24 > surprise Percent
7.0175
Earnings History > 25 > period
2019-09-30
Earnings History > 25 > report Date
2019-11-13
Earnings History > 25 > date
2019-09-30
Earnings History > 25 > before After Market
BeforeMarket
Earnings History > 25 > currency
USD
Earnings History > 25 > eps Actual
-0.54
Earnings History > 25 > eps Estimate
-0.66
Earnings History > 25 > eps Difference
0.12
Earnings History > 25 > surprise Percent
18.1818
Earnings History > 26 > period
2019-06-30
Earnings History > 26 > report Date
2019-08-12
Earnings History > 26 > date
2019-06-30
Earnings History > 26 > before After Market
AfterMarket
Earnings History > 26 > currency
USD
Earnings History > 26 > eps Actual
-1.3
Earnings History > 26 > eps Estimate
-0.64
Earnings History > 26 > eps Difference
-0.66
Earnings History > 26 > surprise Percent
-103.125
Earnings History > 27 > period
2019-03-31
Earnings History > 27 > report Date
2019-05-28
Earnings History > 27 > date
2019-03-31
Earnings History > 27 > before After Market
AfterMarket
Earnings History > 27 > currency
USD
Earnings History > 27 > eps Actual
-1.76
Earnings History > 27 > eps Estimate
-
Earnings History > 27 > eps Difference
0
Earnings History > 27 > surprise Percent
-
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AIdeaya Biosciences Advances with IDE892 Study Targeting MTAP-Deleted Tumors TipRanks
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$49.4706
Analyst Picks
Strong Buy
10
Buy
2
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very High
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 133.99% of the total shares of Ideaya Biosciences Inc
1.
FMR Inc(14.9894%)
since
2025/06/30
2.
BlackRock Inc(10.0893%)
since
2025/06/30
3.
Capital Research Global Investors(7.4765%)
since
2025/06/30
4.
HHG PLC(7.0812%)
since
2025/06/30
5.
American Funds SMALLCAP World A(6.6971%)
since
2025/06/30
6.
Fidelity Growth Compy Commingled Pl S(6.5514%)
since
2025/07/31
7.
Point72 Asset Management, L.P.(5.7372%)
since
2025/06/30
8.
Vanguard Group Inc(5.6387%)
since
2025/06/30
9.
Federated Hermes Inc(5.2796%)
since
2025/06/30
10.
Fidelity Growth Company Fund(4.6686%)
since
2025/07/31
11.
Deerfield Management Co(4.4673%)
since
2025/06/30
12.
State Street Corp(3.8631%)
since
2025/06/30
13.
Logos Global Management LP(3.8166%)
since
2025/06/30
14.
Federated Hermes Kaufmann R(3.083%)
since
2025/06/30
15.
Federated Hermes Kaufmann Growth(3.083%)
since
2025/06/30
16.
Vanguard Total Stock Mkt Idx Inv(2.9334%)
since
2025/07/31
17.
Sofinnova Ventures(2.4506%)
since
2025/06/30
18.
Baker Bros Advisors LP(2.4174%)
since
2025/06/30
19.
Geode Capital Management, LLC(2.4111%)
since
2025/06/30
20.
iShares Russell 2000 ETF(2.3086%)
since
2025/08/31
21.
T. Rowe Price Associates, Inc.(2.1735%)
since
2025/06/30
22.
Federated Hermes Kaufmann Small Cap Grow(2.1108%)
since
2025/06/30
23.
Federated Hermes Kaufmann Small Cap A(2.1108%)
since
2025/06/30
24.
Citadel Advisors Llc(2.0833%)
since
2025/06/30
25.
Pictet Asset Manangement SA(2.0596%)
since
2025/06/30
26.
Fiera Capital Corporation(1.7483%)
since
2025/06/30
27.
Morgan Stanley - Brokerage Accounts(1.6583%)
since
2025/06/30
28.
SPDR® S&P Biotech ETF(1.5297%)
since
2025/08/31
29.
Fidelity Growth Company K6(1.4714%)
since
2025/07/31
30.
Adage Capital Partners Gp LLC(1.4126%)
since
2025/06/30
31.
Goldman Sachs Group Inc(1.4013%)
since
2025/06/30
32.
Fidelity Series Growth Company(1.3036%)
since
2025/07/31
33.
US Small-Cap Growth II Equity Comp(1.203%)
since
2025/06/30
34.
Pictet-Biotech P USD(1.0972%)
since
2025/05/31
35.
Vanguard Institutional Extnd Mkt Idx Tr(1.0719%)
since
2025/07/31
36.
Fidelity Small Cap Index(0.96%)
since
2025/06/30
37.
Janus Henderson Global Life Sciences D(0.8997%)
since
2025/06/30
38.
Janus Henderson Global Life Sciences(0.8997%)
since
2025/06/30
39.
Eventide Healthcare & Life Sciences I(0.8807%)
since
2025/06/30
40.
Janus Henderson US SMID Cap Growth(0.8678%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.8633
Date
2025-09-30
EPS Actual
1.33
EPS Estimate
-0.55
EPS Difference
1.88
Surprise Percent
341.8182%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.